

Wyeth Pharmaceuticals  
500 Arcola Road  
Collegeville, PA 19426

Mike Gladstone  
AVP Gastroenterology and  
Metabolic Diseases



February 27, 2006

Dear Valued Customer:

We recently communicated to you that PROTONIX<sup>®</sup> I.V. (pantoprazole sodium) supply would be limited for six weeks. This situation arose due to a manufacturing investigation that Wyeth initiated at the plant responsible for the manufacture of PROTONIX<sup>®</sup> I.V. In conducting the manufacturing investigation, existing inventory was placed on hold, shipments were suspended, and manufacturing was suspended. The investigation was concluded successfully and shipments of PROTONIX<sup>®</sup> I.V. resumed on February 1, 2006.

To ensure sufficient and consistent supply to our PROTONIX<sup>®</sup> I.V. customers, Wyeth planned to resume full production at the main manufacturing site and to bring two additional PROTONIX<sup>®</sup> I.V. manufacturing sites on line. In order to achieve both objectives, a series of procedures and quality tests needed to be conducted at each facility, and manufacturing operations did resume last week. However, supply will continue to be limited throughout the months of March and April.

Following is important information related to the purchase of PROTONIX<sup>®</sup> I.V.:

- All hospitals and long-term care and home health care facilities will continue to have allocation limits placed on their PROTONIX<sup>®</sup> I.V. ordering
- Similar to February's process, March and April allocations will be determined based upon individual purchase history from April to September of 2005. However, March allocations will be set at **50%** of an average month's usage. We expect to be able to raise April allocations to **85%** of an average month's usage, and anticipate that normal purchasing will resume in May.
- No inventory will be shipped to wholesalers
- Wyeth will drop ship product through wholesalers at the request of a hospital or long-term care or home health care facility

Regarding the PROTONIX Performance Discount Agreement, Wyeth has suspended the second quarter of 2006 performance criteria in addition to the already suspended first quarter performance criteria. As a result, all hospital customers participating in the agreement will receive a discount of 94% off the PROTONIX oral tablets catalog\* price and an 83.38% discount off the PROTONIX<sup>®</sup> I.V. catalog price, regardless of the performance criteria described in the PROTONIX Performance Discount Agreement, for the second half of 2006 (July through December).

If there is an emergency need for additional supply of PROTONIX<sup>®</sup> I.V., please call Wyeth Customer Service at 1-800-666-7248 and we will do our best to assist you. Please understand that these types of requests are for emergency situations only.



The supply of PROTONIX® (pantoprazole sodium) 40 mg delayed release tablets continues to be unaffected by this situation.

We continue to work diligently to solve our supply issue. We recognize the inconvenience that this creates for you and your patients, and as such thank you for your continued cooperation, assistance, and support through this time.

\* Catalog prices are subject to future price increases.

Sincerely,

*Mike Gladstone*

AVP Gastroenterology and Metabolic Diseases